PHILADELPHIA, Pa, May 17, 2021 – PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced that it has been awarded a $456,000 Phase II SBIR supplemental grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of… Read More